- Date 28 Sep 2020
Nuformix a pharmaceutical development company focused on unlocking the therapeutic potential and value of known
drugs to develop novel medicines to provide enhanced benefit, announces it has signed an exclusive
option agreement with Oxilio Ltd (“Oxilio”)
You might also be interested in these articles
Technology
Answer the call for speakers & start-ups for CW's International Conference
None
Thu 7 Nov 2024
CW (Cambridge Wireless Ltd)
Technology
Celebrating the Cambridge Tech Week Innovation Alley Award Winners
None
Wed 2 Oct 2024
CW (Cambridge Wireless Ltd)
Technology
Optalysys wins the Business Weekly and Cambridge Tech Week Scale-Up Business Plan Competition
None
Wed 2 Oct 2024
CW (Cambridge Wireless Ltd)